Note: Descriptions are shown in the official language in which they were submitted.
CA 02455710 2004-O1-09
WO 03/006031 PCT/EP02/07222
CALCIUM SALTS WITH CYTOTOXIC ACTIVITY
The present invention relates to the use of calcium salts, in particular
calcium trifluoroacetate, to prepare medicaments with cytotoxic and
antitumoral activity.
Calcium salts, in particular calcium gluconate, have been used for
s some time in human medicine to treat osteoporosis and all conditions in
which an increase in the blood calcium level is indicated. The use of
calcium salts to treat tumoral and hyperproliferative disorders has not been
described to date; however, possible chemoprotective effects have been
postulated for some calcium salts, in particular calcium glucarate.
lo It has now been found that some calcium salts, in particular calcium
trifluoroacetate, have a surprising cytotoxic activity which is selective for
tumour cells. This activity has been demonstrated on cell line cultures of
human and murine tumours of various origins (colon, lung, pancreas, breast,
prostate, liver, stomach and ovaries) such as HT 29, Kato, C-26, H G C 27
and PA-1 cells.
Calcium trifluoroacetate, prepared with conventional methods from
trifluoroacetic acid and calcium oxide or hydroxide, and added to each well
(~ 10,000 cells) in an aqueous solution in quantities ranging between 0.001
and 1.5 mg, causes the death of 90-95% of tumour cells or more. Under the
2o same conditions, normal human cell lines proved almost insensitive or at
least considerably less sensitive to the cytotoxic effect attributable to
calcium trifluoroacetate. Similar effects have been obtained with other
calcium salts of pharmaceutically acceptable acids, such as acetate, nitrate,
chloride and the like, though to a lesser extent. However, trifluoroacetate
2s seems to be preferable in view of its favourable toxicological properties.
For use in the treatment of tumours, calcium trifluoroacetate or other
CA 02455710 2004-O1-09
WO 03/006031 PCT/EP02/07222
2
calcium salts will preferably be administered parenterally, for example by
the intramuscular, intravenous or subcutaneous route, at doses ranging
between 0.1 and 10 mg/kg/day. For this purpose, the calcium salt will be
suitably formulated in the form of sterile suspensions or solutions, possibly
s with the aid of conventional vehicles or solvents. However, other
administration routes would also be possible, such as the oral route or
topical infusion at the site of the tumour lesion. Calcium salts, and in
particular calcium trifluoroacetate, can be used in combination with other
antitumoral drugs which have complementary, synergistic or otherwise
1o useful activity.
Other disorders in which antiproliferative activity or control of cell
growth is indicated can also be treated in addition to tumours.
The results of experiments carried out with calcium trifluoroacetate are
set out below.
is Toxicity in mouse and rat
Calcium trifluoroacetate, administered at the acute dose of 200 mg/kg
to Balb/c mice by the intraperitoneal route, does not produce any
noteworthy toxic effects.
Four weeks' sub-chronic treatment at the dose of 100 mg/kg, again by
2o the intraperitoneal route, did not cause any pathological effects. A
similar 4
week treatment by the subcutaneous route was well tolerated at the dose of
mg/kg.
In Sprague Dawley rats, toxic effects were not observed after acute or
sub-acute administration of 200 mg/kg of calcium trifluoroacetate by the
25 intravenous route.
In vitro cytotoxicity
The cytotoxicity of calcium trifluoroacetate has been determined on 13
cell lines of malignant human tumours and 4 lines of benign tumours.
CA 02455710 2004-O1-09
WO 03/006031 PCT/EP02/07222
3
20 ~1 of Ca(CF3C00)2 solutions at concentrations of 100, 50, 37.5, 25,
1 S, 12.5, 10 and 6.25 mg/ml are added to 96-well plates, each containing
10,000 cells/well in 100 ~,1 of culture medium.
They are left overnight at 37°C, after which 40 ~l of MTT
s (dimethylthiazole-0.2 g/100 ml PBS) is added, and they are left for 4 hours
at 37°C.
After aspiration, 100 ~1 of SDS is added and they are left at 37°C
for 1
hour. The plate is read at 540 nm and 690 nm.
The toxicity of the sample is evaluated as the ratio between the
absorbance value in the well with the treated cells and the absorbance value
in the well with the control cells.
Absorbance of cells + sample
1 - x 100 = % dead cells
Absorbance of control cells
is The MTT test is a quantitative colorimetric method that measures only
live cells, because the mitochondria) enzymes of live cells are able to
transform MIT tetrazolium salts into insoluble formazan.
The results are summarised in Table 1.
CA 02455710 2004-O1-09
WO 03/006031 PCT/EP02/07222
4
TABLE 1
Biological activity of Ca(CF3C00)2 in vitro
CELL LINES Concentration er
of well
Ca
CF
COO
in
vitro
2000 1000 750 500 300 250 200 125
HEP G-2 100 83 75 68 37 29 18 17
MG 63 100 93 74 60 53 45 32 27
HGC-27 100 94 94 85 76 54 33 24
A-172 100 83 70 60 58 47 32 25
PSN-1 100 95 94 94 92 92 91 86
C-26 100 88 88 87 80 70 55 47
DU-145 85 78 77 67 65 50 33 22
KATO 94 84 70 59 52 35 29 7
CHANG 41 33 33 27 25 19 16 11
NCTC 36 34 32 30 25 22 19 19
MCF-7 42 41 25 24 23 22 7 7
T47D 48 44 41 37 34 31 30 28
FTC-238 82 77 75 63 35 25 20 13
W 138 82 76 67 52 48 34 31 23
CCD-8L U SS 42 39 32 I 5 4 0
S
PA-1 100 100 100 98 97 96 70 52
HT-29 95 89 76 69 60 50 47 32
Normal type: malignant cell lines
s Bold italic type: benign cell lines
RESULTS
Malignant human cell lines of different histological types and origins
demonstrate that the cytotoxic response to calcium trifluoroacetate differs
between the various lines but, depending on dose, always reaches very high
1o cell death levels: 8/14 reached 100% mortality, and 6/14 reached values
ranging between 80% and 90%.
These results were obtained after 24 hours' incubation. Checks were
performed after 6 hours in view of the possibly rapid turnover of the salt
due to its very low molecular weight.
~s The data collected demonstrate that antitumoral activity takes place in
a short time at low concentrations. If the concentration is increased, a non-
CA 02455710 2004-O1-09
WO 03/006031 PCT/EP02/07222
specific toxicity of the salt develops which explains its low toxicity towards
normal cells at high doses.
Experimental murine tumours
Balb/C mice were inoculated with 2$,000 cells/mouse of C26 (murine
s colon adenocarcinoma).
Four days after the inoculation, the animals were treated
subcutaneously with $ mg/kg of calcium trifluoroacetate. The control group
received saline only. The treatment was given every day. The tumour
diameter was measured with a caliper gauge. On the 20th day after the
to inoculation the animals were killed and the tumours removed and weighed.
The results are set out in Table 2. The mean weight and mean size of the
tumours in the control mice were four times greater than those of the treated
group. The data relating to the onset of tumours were also significant: 100%
for the controls as against 40% for the treated mice.
CA 02455710 2004-O1-09
WO 03/006031 PCT/EP02/07222
~1 ~ N
O '''?
~ N O
~ O ~ ~ O M ~ -1-I
N -E-~ ~
~ ~G M ~O O
p ~ 00 O
et
O
O .-i O ~ O
O O N
00
N O
U
v~ ao
N
O ~ l~ N + ~ ~ d 01
N l~ N
E"~ ~ ~ +I
b ,--,,.-,,~,~..-, zzz~~
~ N
W
0
d d d oo
.~
o ~b ~~~~~. ~~ 'z'z'zo.~ y
N M
N W ~ r1 C
U E~
~
o
o M
O
W .y o, o, a, o d d d r,
t~ o0 oo
~b oooao +~ 'zz'z~~ +~
d ~ 0~0 N
O O
W
O
t~ ~O
o o
~~~dd dddd~
~b ~~~z'z ~ 'z'zz'z~ +~
M
O
H
A O A
~ O 'r'U 'i'
~ ~ U
"
U a
O on
U
H
a
O
U ~ N M ~t E"~ ~ N M ~'
V~ ~ ~
CA 02455710 2004-O1-09
WO 03/006031 PCT/EP02/07222
7
Treatment of spontaneously occurring canine tumours
Experiments carried out on spontaneously occurring tumours in
domestic animals, especially dogs, are considered a reliable model which is
predictive of activity in man (D.M Vail et al., Spontaneously occurring
tumors in companion animals as models for drug development. Anticancer
drug development guide: preclinical screening, clinical trials and approval.
Edited by B. Teicher Humana Press Inc., Totowa, NJ). Tumours in pets are
more similar than rodent tumours to human tumours in terms of size, cell
kinetics and behaviour.
1o Six dogs suffering from mammary tumours and one dog with a
malignant lymphoma were treated. The treatment was given intravenously at
doses ranging between 100 and 10 mg/kg/day of calcium trifluoroacetate.
Despite some variability among animals, depending on the onset of side
effects, especially vomiting, the highest dose (100 mg/kg) was administered
initially for one to three days, followed by the lowest dose (10 mg/kg) for a
few days. The highest dose was then reintroduced, but only given twice a
week. Some animals were always treated with the highest dose, but at a
lower frequency (9-10 administrations in approx. 20 days).
Although the results are of a preliminary nature and were obtained on a
limited number of animals, they demonstrate the considerable antitumoral
efficacy of calcium trifluoroacetate. In fact, the experiments demonstrated:
1. A reduction in the main tumour mass of 20% to over 50% of its initial
volume. This reduction was evident after the first few administrations,
and peaked at the end of the treatment cycle used so far (generally 3
weeks).
2. The reduced volume was generally accompanied by other phenomena
involving the tumour mass such as colliquative necrosis, loss of contact
with the surrounding tissues (adhesions) and finally, encapsulation or
CA 02455710 2004-O1-09
WO 03/006031 PCT/EP02/07222
g
rupture of the wall, with leakage of necrotic material to the exterior.
3. Arrested development of metastases and, in some cases, necrosis, and
their disappearance (resorption or calcification).
4. Ca(CF3C00)2 proved totally safe even at daily intravenous doses of 100
s mg/kg; the only side effect, observed in two animals, was vomiting
immediately after administration of the drug, and a slight increase in
temperature (not exceeding 1 °C).
The toxicity tests, performed by monitoring the liver and kidney function
parameters and coagulation times with particular care, did not indicate any
to pathological modification of those parameters in the treated animals.
Clinical cases
Calcium trifluoroacetate was administered subcutaneously at doses
ranging between 10 and 200 mg a day to five patients aged 56 to 63
suffering from cancer of the breast (one case), colon (three cases) and womb
is (one case), at advanced state of disease and with diffuse metastasis.
Except
for one case of colon cancer which ended in the death of the patient due to
the highly advanced state of the disease (all cases were treated on the basis
of a compassionate protocol for obvious ethical reasons), the therapeutic
response was surprising, both in objective terms (approx. 10 to 40%
2o reduction in tumour mass, reduction or disappearance of ascites and
metastatic nodes, and a reduction in tumour markers such as CA19.9 and
alpha-fetoprotein) and in subjective terms (improved mood, reduction and
disappearance of pain, and return to working and social life). Even in the
case of the patient who died, a reduction in the tumour mass was observed,
2s but the patient died due to aggravation of neoplastic cachexia and
cardiorespiratory complications.
